The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

An unusual tale of discovery led to the 2006 finding of a protein expressed on the surface membrane of many types of cancerous cell, but only found on the inside of healthy cells 1. Today, this ...

Mark Ratain’s First Opinion piece of Feb. 4, 2025, implies that the oncologists in NCI’s Investigational Drug Branch (IDB) colluded with the drug company Exelixis to sponsor two Phase 3 studies of its ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...

AstraZeneca has entered a global licensing agreement with Jacobio Pharmaceuticals, a Hong Kong-listed Chinese biotech company, to develop and commercialize a clinical-stage KRAS cancer drug candidate, ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...

Scripps Research scientists developed a technique that maps drug binding in individual cells throughout the body, potentially ...